- Home
- GENK vs IRD Comparison
GENK vs IRD Comparison
Compare GENK & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- IRD
- Stock Information
- Founded
- GENK 2011
- IRD 2018
- Country
- GENK United States
- IRD United States
- Employees
- GENK N/A
- IRD N/A
- Industry
- GENK Restaurants
- IRD
- Sector
- GENK Consumer Discretionary
- IRD
- Exchange
- GENK Nasdaq
- IRD NYSE
- Market Cap
- GENK 36.5M
- IRD 36.0M
- IPO Year
- GENK 2023
- IRD N/A
- Fundamental
- Price
- GENK $5.50
- IRD $1.13
- Analyst Decision
- GENK Strong Buy
- IRD Strong Buy
- Analyst Count
- GENK 3
- IRD 1
- Target Price
- GENK $13.17
- IRD $8.00
- AVG Volume (30 Days)
- GENK 60.1K
- IRD 150.5K
- Earning Date
- GENK 03-05-2025
- IRD 02-24-2025
- Dividend Yield
- GENK N/A
- IRD N/A
- EPS Growth
- GENK 483.78
- IRD N/A
- EPS
- GENK 0.17
- IRD N/A
- Revenue
- GENK $198,834,000.00
- IRD $8,381,000.00
- Revenue This Year
- GENK $14.66
- IRD N/A
- Revenue Next Year
- GENK $21.47
- IRD $29.37
- P/E Ratio
- GENK $31.92
- IRD N/A
- Revenue Growth
- GENK 12.50
- IRD N/A
- 52 Week Low
- GENK $5.46
- IRD $0.81
- 52 Week High
- GENK $14.46
- IRD $2.71
- Technical
- Relative Strength Index (RSI)
- GENK 19.19
- IRD N/A
- Support Level
- GENK $5.50
- IRD N/A
- Resistance Level
- GENK $6.42
- IRD N/A
- Average True Range (ATR)
- GENK 0.32
- IRD 0.00
- MACD
- GENK -0.04
- IRD 0.00
- Stochastic Oscillator
- GENK 2.88
- IRD 0.00
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.